Direct immunomodulatory influence of IFN-β on human astrocytoma cells

Immunopharmacology and Immunotoxicology

Volumn 37, Issue 2, 2015, Pages 214-219

  Mohsenzadegan, Monireh ^a   Fayazi, Mohammad Reza ^a   Abdolmaleki, Mohsen ^b   Bakhshayesh, Masoomeh ^a   Seif, Farhad ^c   Mousavizadeh, Kazem ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Astrocytoma cells; IFN ; IL 10; iNOS; MMP 9; TIMP 1

Indexed keywords

GAMMA INTERFERON; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERFERON BETA 1A; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; BETA INTERFERON; IL10 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; NOS2 PROTEIN, HUMAN;

ARTICLE; ASTROCYTE; ASTROCYTOMA CELL; ASTROCYTOMA CELL LINE; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; ASTROCYTOMA; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ASTROCYTOMA; CELL LINE, TUMOR; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERLEUKIN-10; NITRIC OXIDE SYNTHASE TYPE II;

EID: 84924702624     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2015.1014559     Document Type: Article

References (37)

1. Pivneva TA. Microglia in normal condition and pathology. Fiziol Zh 2008;54:81-89.
2. Mirshafiey A. Venom therapy in multiple sclerosis. Neuropharmacology 2007;53:353-361.
3. Brück W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol 2005;252:v3-v9.
4. Reske D, Thomas AV, Petereit HF, et al. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors. Neuroimmunomodulation 2009;16:385-391.
5. Kasper LH, Reder AT. Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol 2014;1:622-631.
6. Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011;1:491-502.
7. Brosnan CF, Raine CS. The astrocyte in multiple sclerosis revisited. Glia 2013;61:453-465.
8. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008;65:2702-2720.
9. Saha RN, Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid Redox Signal 2006;8:929-947.
10. Broholm H, Andersen B, Wanscher B, et al. Nitric oxide synthase expression and enzymatic activity in multiple sclerosis. Acta Neurol Scand 2004;109:261-269.
11. Petković F, Blaževski J, Momčilović M, et al. Nitric oxide inhibits CXCL12 expression in neuroinflammation. Immunol Cell Biol 2013;91:427-434.
12. Calabrese V, Scapagnini G, Ravagna A, et al. Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine. Neurochem Res 2003;28:1321-1328.
13. Li YH, Liu CY, Zhang PJ, et al. Effect of Fasudil on miroglia and astrocytes in experimental autoimmune encephalomyelitis mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012;28:1242-1245 [in Chinese].
14. Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009;31:13-29.
15. Agrawal SM, Yong VW. Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:99-126.
16. Könnecke H, Bechmann I. The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clin Dev Immunol 2013;2013:914104.
17. Karabudak R, Kurne A, Guc D, et al. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J Neurol 2004;251:279-283.
18. Miljković D, Timotijević G, Mostarica Stojković M. Astrocytes in the tempest of multiple sclerosis. FEBS Lett 2011;585:3781-3788.
19. Liu BS, Janssen HL, Boonstra A. Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. Eur J Immunol 2012;42:2431-2440.
20. Ersoy E, Kuş CN, Sener U, et al. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur J Neurol 2005;12:208-211.
21. Imitola J, Chitnis T, Khoury SJ. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005;106:163-177.
22. Byrnes AA, McArthur JC, Karp CL. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002;51:165-174.
23. Waubant E, Gee L, Bacchetti P, et al. Relationship between serum levels of IL-10, MRI activity and interferon beta-1a therapy in patients with relapsing-remitting MS. J Neuroimmunol 2001;112:139-145.
24. Rentzos M, Nikolaou C, Rombos A, et al. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clin Neurol Neurosurg 2008;110:992-996.
25. González H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol 2014;274:1-13.
26. Gresa-Arribas N, Vié itez C, Dentesano G, et al. Modelling neuroinflammation in vitro: a tool to test the potential neuroprotective effect of anti-inflammatory agents. PLoS One 2012;7:e45227.
27. Graber JJ, Ford D, Zhan M, et al. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 2007;185:168-174.
28. Zhang L, Yuan S, Cheng G, Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS One 2011;6:e28432.
29. Ho HJ, Huang DY, Ho FM, et al. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase expression by endoplasmic reticulum stress. Cell Signal 2012;24:2166-2178.
30. Louin G, Marchand-Verrecchia C, Palmier B, et al. Selective inhibition of inducible nitric oxide synthase reduces neurological deficit but not cerebral edema following traumatic brain injury. Neuropharmacology 2006;50:182-190.
31. Jafarian-Tehrani M, Louin G, Royo NC, et al. 1400W, a potent selective inducible NOS inhibitor, improves histopathological outcome following traumatic brain injury in rats. Nitric Oxide 2005;12:61-69.
32. Yoo BK, Choi JW, Shin CY, et al. Activation of p38 MAPK induced peroxynitrite generation in LPS plus IFN-gamma-stimulated rat primary astrocytes via activation of iNOS and NADPH oxidase. Neurochem Int 2008;52:1188-1197.
33. Guthikonda P, Baker J, Mattson DH. Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol 1998;82:133-139.
34. Yushchenko M, Mäder M, Elitok E, et al. Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. J Neurol 2003;250:1224-1228.
35. Sellebjerg F, Sorensen TL. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 2003;61:347-355.
36. Leppert D, Waubant E, Burk MR, et al. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852.
37. Liuzzi GM, Latronico T, Fasano A, et al. Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler 2004;10:290-297.